Maze Therapeutics has jumped more than 80% in 3 months. Its CEO is bullish on what’s to come

In this article

MAZE

Follow your favorite stocks CREATE FREE ACCOUNT

Maze Therapeutics has had a great run since its initial public offering in January — and CEO Jason Coloma is hoping that momentum continues as the company works on getting kidney-disease drugs to the market.

Maze Therapeutics, a clinical-stage biopharmaceutical company, made its public debut on the Nasdaq stock exchange on January 31 at $16.12 a share, compared to its IPO price of $16. These days it's trading above $32.

The company also made CNBC's list of top performing stocks of companies based in San Francisco . To find the names, CNBC screened for companies headquartered in the area with market caps above $500 million. We then screened for the top performers over the last three months via FactSet.